Portal de investigación
- Inicio
- Publicaciones
- A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Orally Administered LP-108 (Lacutoclax) As Monotherapy and in Combination with Azacitidine in Subjects with Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Orally Administered LP-108 (Lacutoclax) As Monotherapy and in Combination with Azacitidine in Subjects with Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Burgues, Juan Miguel Bergua
- Koenig, Kristin
- Bixby, Dale L.
- Burke, Patrick W.
- Daver, Naval
- Anthony, Stephen P.
- Tan, Fenlai
- Chen, Yi
- Chen, Yu
- Aviles, Ignacio Casas
- Curran, Emily K.
Grupos
Abstract
Abstract no disponible
Datos de la publicación
- ISSN/ISSNe:
- 0006-4971, 1528-0020
- Tipo:
- Meeting Abstract
- Páginas:
- 6009-6010
- Factor de Impacto:
- 4,834 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
BLOOD ELSEVIER
Documentos
- No hay documentos
Filiaciones
Filiaciones no disponibles
Campos de Estudio
Cita
Burgues,JMB,Koenig,K,Montesinos,P,Bixby,DL,Burke,PW,Daver,N,Anthony,SP et al. A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Orally Administered LP-108 (Lacutoclax) As Monotherapy and in Combination with Azacitidine in Subjects with Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS:ELSEVIER. 2024 p.p. 6009-6010.